{"id":"W2890915407","doi":"10.1200/jco.2017.35.15_suppl.tps8052","title":"CheckMate 602: An open-label, randomized, phase 3 trial of combinations of nivolumab, elotuzumab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pomalidomide; Medicine; Nivolumab; Internal medicine; Pembrolizumab; Lenalidomide; Dexamethasone; Oncology; Refractory (planetary science); Progressive disease; Multiple myeloma; Immunotherapy; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001538353,0.001975843,0.001689287,0.000624762,0.000407545,0.001552496,0.001405858,0.001886369,0.009771503],"category_scores_gemma":[0.001165537,0.0006379617,0.001610054,0.000487142,0.0009243838,0.001151303,0.0005131818,0.002994183,0.001239361],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001433147,"about_ca_system_score_gemma":0.001356269,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001767621,"about_ca_topic_score_gemma":0.005030017,"domain_scores_codex":[0.9996173,0.00016884,0.00001764305,0.0000766934,0.00004464446,0.00007483003],"domain_scores_gemma":[0.9992973,0.0001250982,0.0001694635,0.00003610551,0.0000328973,0.0003390652],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9359331,0.01637027,0.001532247,0.000883618,0.001194121,0.0001095018,0.00009524375,0.000895894,0.007578729,0.000368971,0.003962012,0.03107621],"study_design_scores_gemma":[0.9122909,0.08178198,0.002416928,0.00004155888,0.0003344886,0.00007486314,0.00002403633,0.000589758,0.0005845795,0.0001652085,0.001676283,0.00001930505],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9735217,0.005559634,0.0007261164,0.001163739,0.0005383092,0.00790156,0.004391937,0.0003343531,0.005862613],"genre_scores_gemma":[0.9750587,0.002633625,0.001813565,0.002906765,0.0003868174,0.006230096,0.004949678,0.00005918153,0.005961516],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009771503,"threshold_uncertainty_score":0.03268892,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2646944539655388,"score_gpt":0.5483476067111028,"score_spread":0.283653152745564,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}